EPM speaks to Chris Allen, CEO of scientific consultancy and Contract Research Organisation (CRO) Broughton, which has just launched a new inhalation testing service.
For more than 70 years, polymer specialist Raumedic has partnered with companies and practitioners to develop solutions for medical and pharmaceutical applications.
A new report published by Connect in Pharma highlights a range of forces shaping the future of the pharmaceutical manufacturing and drug-delivery fields, from machine learning and connected devices to eco-friendly strategies.
SHL Medical discusses the evolution of drug formulations and how it’s supporting cartridge-based subcutaneous drug delivery in redefining the field of patient self-injection.
Andrew Lee, senior consultant at lab services and consultancy specialist, Broughton, reports that packaging selection is an important consideration for many drug products, particularly pressurised metered dose inhalers (pMDIs).
Michael Earl, director, pharmaceutical services at Owen Mumford, examines the benefits that patients are set to receive as the connected drug delivery devices market grows.
Phillips-Medisize, a Molex company and specialist in the design and manufacture of drug delivery, diagnostic and medtech devices, has expanded its product portfolio with the introduction of a disposable pen injector.
Birmingham Biotech announced new evidence from the University of Birmingham that shows NoriZite Nasal Spray can block the infection of the Omicron variant of SARS-CoV-2 in lab-based tests.
Dr. Sandeep Kumar, Formulation Development manager, Colorcon, sheds light on how selecting an excipient in early formulation development is critical to developing a robust scalable SOD formulation and can help the transition from capsule to tablet.
BD and Biocorp joined forces to improve the outcomes and adherence of self-administered drugs through connected drug delivery, by combining the use of digital technology with prefillable syringes.
Dr. Nveed Chaudhary, chief scientific and regulatory officer at Broughton, shares how developments in inhaled drug delivery technology could both improve the treatment of diseases, and enable the delivery of a wider range of active substances.
Particle Works launches its second platform, the Automated Library Synthesis (ALiS) System, enabling automation and high-throughput screening of lipid nanoparticle (LNP) formulations and mRNA candidates in early-stage drug development.
